Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

SOP for Microbiological Stability Testing of Liposomes

Posted on By

SOP for Microbiological Stability Testing of Liposomes

Microbiological Stability Testing of Liposomes

1) Purpose

The purpose of this SOP is to outline the procedure for conducting microbiological stability testing on liposome formulations. This testing ensures that the liposomes remain free from microbial contamination during storage, thereby maintaining product quality and safety over the defined shelf life.

2) Scope

This SOP applies to personnel involved in the microbiological testing of liposomal formulations, including quality control and microbiology teams. It covers the evaluation of microbial contamination over time and ensures compliance with regulatory standards for sterile or non-sterile formulations.

3) Responsibilities

  • QC Microbiology Team: Responsible for performing microbiological tests at specified intervals and documenting the results.
  • QA Team: Responsible for reviewing and approving the test results and ensuring compliance with GMP standards.
  • Formulation Scientists: Responsible for preparing sterile samples for microbiological testing and ensuring that the production process complies with microbial control procedures.
See also  SOP for Reverse Phase Evaporation Method for Liposome Preparation

4) Procedure

4.1 Sample Preparation

  • 4.1.1 Prepare liposomal formulations in sterile containers, ensuring that samples are representative of the production batch.
  • 4.1.2 Label the samples with the batch number, preparation date, and storage conditions.
  • 4.1.3 Store samples under controlled conditions as required by the stability testing protocol (e.g., 25°C/60% RH, 40°C/75% RH).

4.2 Microbiological Testing Parameters

The following microbiological tests should be performed at specified

intervals to monitor contamination levels:

  • 4.2.1 Total Aerobic Microbial Count (TAMC): Perform microbial enumeration to determine the total number of viable aerobic microorganisms in the liposomal formulation.
  • 4.2.2 Total Yeast and Mold Count (TYMC): Perform microbial enumeration to determine the total number of viable yeast and mold colonies.
  • 4.2.3 Pathogen Detection: Test for the presence of specific pathogens (e.g., Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli) using selective media.
See also  SOP for Preparation of Double Emulsions (W/O/W or O/W/O)

4.3 Testing Schedule

  • 4.3.1 Initial Test: Conduct microbiological tests immediately after formulation preparation to establish a baseline for contamination levels.
  • 4.3.2 Interim Tests: Perform microbiological testing at specified intervals (e.g., 1 month, 3 months, 6 months) during storage under various conditions.
  • 4.3.3 Final Test: Conduct a final microbiological test at the end of the stability study (e.g., 12 months) to confirm product sterility or bioburden.

4.4 Data Recording and Analysis

  • 4.4.1 Record all test results in the Microbiological Stability Test Report (see Annexure 1 for the template).
  • 4.4.2 Compare the results against the baseline and regulatory limits to assess microbiological stability over time.
  • 4.4.3 Analyze any trends in microbial growth to determine the risk of contamination and evaluate the effectiveness of the preservation system.

4.5 Acceptance Criteria for Microbiological Stability

The liposomal formulation is considered microbiologically stable if the following criteria are met throughout the study:

  • 4.5.1 The total aerobic microbial count (TAMC) remains within acceptable limits (as defined by regulatory guidelines).
  • 4.5.2 The total yeast and mold count (TYMC) remains within acceptable limits.
  • 4.5.3 No specific pathogens are detected during the study period.
See also  SOP for Chemical Stability Testing of Emulsion Formulations

5) Abbreviations

  • TAMC: Total Aerobic Microbial Count
  • TYMC: Total Yeast and Mold Count
  • QC: Quality Control
  • QA: Quality Assurance

6) Documents

  • Microbiological Stability Test Report
  • Batch Manufacturing Record (BMR)
  • Microbial Enumeration Test Report
  • Pathogen Detection Report

7) References

  • USP <61>: Microbiological Examination of Non-Sterile Products
  • ICH Q6A: Specifications for New Drug Substances and Products

8) SOP Version

Version 1.0

Annexure

Annexure 1: Microbiological Stability Test Report Template

Time Point Storage Condition TAMC (cfu/mL) TYMC (cfu/mL) Pathogens Operator Initials
Initial 25°C/60% RH Below Limit Below Limit None Operator Name
1 Month 40°C/75% RH Below Limit Below Limit None Operator Name
3 Months 40°C/75% RH Below Limit Below Limit None Operator Name
Liposome and Emulsion Formulations Tags:Antioxidants in emulsions, API incorporation in emulsions, API incorporation in liposomes, Chemical stability testing liposomes, Cosmetic emulsion formulation, Emulsion droplet size analysis, Emulsion formulation SOP, Emulsion microbiological stability, Emulsion stability testing, Freeze-thaw stability testing, Heat-sensitive liposomes, High-shear mixing emulsions, Liposomal drug delivery SOP, Liposomal vaccines SOP, Liposome formulation SOP, Liposome particle size analysis, Liposome preparation procedure, Liposome size distribution, Liposome stability testing, Nanoemulsion SOP, Parenteral emulsion preparation, pH-responsive emulsions, Physical stability liposomes, Self-emulsifying drug delivery systems (SEDDS), Thin-film hydration liposomes

Post navigation

Previous Post: SOP for Preparation of Nanoparticles for Nasal Delivery
Next Post: SOP for Incorporation of Targeting Ligands in Nanoparticle Formulations

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version